secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K
Filed at:   2026-03-24T23:59:59+00:00
Accession:  0001104659-26-033839
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TELA Bio Q4 2025 revenue $20.9M (+18% YoY); guides FY26 growth at least 8%
--------------------------------------------------------------------------

- Q4 2025 revenue $20.9M (+18% YoY); FY 2025 revenue $80.3M (+16% YoY).
- Net loss Q4 2025 $9.0M vs $9.2M prior year; FY net loss $38.8M vs $37.8M.
- Closed $70M credit facility from Perceptive Advisors; $60M drawn at closing, $10M option by Apr 2027.
- Promoted Howard Langstein, MD, FACS to Chief Medical Officer effective March 1, 2026.
- FY 2026 revenue guidance: at least 8% growth; Q1 2026 revenue expected ~$18.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465926033839/0001104659-26-033839-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465926033839/tm269387d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-033839

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer